Cleviprex Emulsion
Product Images NDC 10122-610
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 12 technical images submitted to the FDA as part of the official labeling for Cleviprex (NDC 10122-610). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Chiesi Usa, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Product Images & Figures Index
Package Label (Principal Display Panel)
This is a set of instructions for storing and administering medication via a vial stored in a carton. The vial should be kept refrigerated at 2-6°C (36-46°F) and protected from light. If transported at room temperature (25°C or 77°F) it should be used within 2 months of the expiration date on the carton. The label number is CTCP-028-0322-01. Before use, gently invert the vial. No further information is available.*
Package Label (Principal Display Panel)
The text describes Clevidipine, an injectable emulsion containing 50 mg/ml of clevidipine. It is stored under refrigerated conditions and can be stored for up to 2 months at room temperature in its carton. The emulsion is packaged in single-use vials that should be used promptly after opening or within 12 hours. It contains EDTA, which inhibits microbial growth up to 12 hours, but contamination can cause life-threatening illness. The product is manufactured by Fresenius Kabi in Austria and contraindicated for patients with allergies to soy or eggs, bile duct obstruction, or severe aortic stenosis. The dosage should be determined by the accompanying package insert, and unused portions should be discarded.*
Package Label (Principal Display Panel)
Figure 1. Mean Change In Systolic Blood Pressure (mmhg) During 30-minute Infusion, Escape-1 (preoperative) (Cleviprex 2)
Figure 2. Mean Change In Systolic Blood Pressure (mmhg) During 30-minute Infusion, Escape-2 (postoperative) (Cleviprex 3)
The text describes a chart or graph showing the mean change from baseline systolic blood pressure measured in mmHg over a 30-minute infusion. The chart appears to show some participants leaving early and only providing data at certain time intervals. The time intervals provided are at 10, 15, 20, 25, and 30 minutes.*
Figure 3. Mean Change In Heart Rate (bpm) During 30-minute Infusion, Escape-1 (preoperative) (Cleviprex 4)
Figure 4. Mean Change In Heart Rate (bpm) During 30-minute Infusion, Escape-2 (postoperative) (Cleviprex 5)
Figure 5. Mean Percent Change In Sbp (%) During The First 30 Minutes Of Infusion, Velocity (severe Hypertension) (Cleviprex 6)
Package Label (Principal Display Panel)
Package Label (Principal Display Panel)
This is a description of a medication containing 25 milligrams of a substance called Contont in a 50 milliliter solution with a concentration of 0.5 milligrams per milliliter. The medication is stored in a vial and should be kept at room temperature. The NDC number is 1012261001. Dosage information is provided in the package insert, and the medication should not be used after the expiration date indicated on the carton or vial, or 2 months after the date indicated on the carton. The medication should not be used in patients with allergies and should not be refrigerated or frozen. Additional administration precautions are also provided.*
Package Label (Principal Display Panel)
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.